Enzyme Replacement Therapy for Neurodegenerative Diseases

Enzyme Replacement Therapy for Neurodegenerative Diseases

Introduction

Enzyme Replacement Therapy for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Enzyme Replacement Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Disorder</td>
<td>Enzyme</td>
</tr>
<tr>
<td class="label">Gaucher disease (Type 2/3)</td>
<td>beta-glucocerebrosidase</td>
</tr>
<tr>
<td class="label">Pompe disease</td>
<td>Acid alpha-glucosidase</td>
</tr>
<tr>
<td class="label">Fabry disease</td>
<td>alpha-galactosidase A</td>
</tr>
<tr>
<td class="label">Mucopolysaccharidosis I</td>
<td>alpha-L-iduronidase</td>
</tr>
<tr>
<td class="label">Mucopolysaccharidosis II</td>
<td>Iduronate sulfatase</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Brineura (cerliponase alfa)</td>
<td>CLN2 disease</td>
</tr>
<tr>
<td class="label">Cerezyme (imiglucerase)</td>
<td>Gaucher disease</td>
</tr>
<tr>
<td class="label">Myozyme (algucosidase alfa)</td>
<td>Pompe disease</td>
</tr>
<tr>
<td class="label">Fabrazyme (agalsidase beta)</td>
<td>Fabry disease</td>
</tr>
</table>

Enzyme replacement therapy (ERT) is a treatment approach that involves administering exogenous enzymes to compensate for deficient or defective endogenous enzymes. While historically successful for lysosomal storage disorders, ERT is being explored for neurodegenerative diseases where specific enzyme deficiencies contribute to pathology, or where enzyme administration can reduce toxic protein accumulation. [@schiffmann2024]

Mechanism of Action

Enzyme replacement therapies work through several mechanisms: [@schultz2024]

Applications in Neurodegenerative Diseases

Lysosomal Storage Disorders with CNS Involvement

Several lysosomal storage disorders cause neurodegenerative phenotypes: [@m2024]

Emerging Applications for Neurodegeneration

Gaucher Disease and Parkinson's

• β-Glucocerebrosidase (GCase) — The [GBA1](/genes/gba) gene mutations are the most common genetic risk factor for PD
• ERT with recombinant glucocerebrosidase may reduce [α-synuclein](/proteins/alpha-synuclein) aggregation
• Clinical trials ongoing for PD with GBA mutations

Ceroid Lipofuscinosis (Batten Disease)

• CLN2 disease (Late Infantile) — Tripeptidyl peptidase 1 deficiency
• Brineura (cerliponase alfa) — First FDA-approved enzyme therapy for CNS disease
• Administered via intracerebroventricular infusion
• Slows disease progression significantly

Targeting Amyloid and Tau Pathology

• [Neprilysin](/entities/neprilysin) — [Aβ](/proteins/amyloid-beta)-degrading enzyme
• [Insulin-degrading enzyme](/entities/insulin-degrading-enzyme) — Degrades Aβ and [tau](/proteins/tau)
• Cathepsin B — Aβ-degrading protease

Delivery Challenges

Blood-Brain Barrier Penetration

The main challenge for CNS-directed ERT:

• Intrathecal administration
• Intracerebroventricular infusion
• AAV-mediated gene therapy (converts cells into enzyme factories)
• Receptor-mediated transcytosis
• Focused ultrasound-mediated delivery

Immunogenicity

• Immune responses against foreign enzymes
• Antibody formation can reduce efficacy
• Immune tolerance induction strategies

Clinical Development

Approved Therapies

Investigational Therapies

Combination Approaches

Enzyme replacement may be combined with:

• [Substrate reduction therapy](/therapeutics/substrate-reduction-therapy) — Complementary mechanisms
• [Chaperone therapy](/therapeutics/enzyme-chaperone-therapy) — Enhance residual enzyme activity
• [Gene therapy](/therapeutics/gene-editing-neurodegeneration) — Long-term expression

Advantages and Limitations

Advantages

• Well-established therapeutic platform
• Targeted mechanism of action
• Can provide rapid clinical benefit
• May modify disease progression

Limitations

• Requires chronic administration
• Limited CNS penetration
• Potential immunogenicity
• High cost
• Doesn't address genetic cause

See Also

• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Gaucher Disease](/diseases/gaucher-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Enzyme Chaperone Therapy](/therapeutics/enzyme-chaperone-therapy)
• [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration)
• [GBA1 Gene](/genes/gba)

External Links

• [ClinicalTrials.gov: Enzyme Replacement](https://clinicaltrials.gov/search?cond=neurodegenerative+disease&intr=enzyme+replacement)
• [National Gaucher Foundation](https://www.gaucherdisease.org/)
• [Batten Disease Support and Research Association](https://bdsra.org/)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
• [Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA
• [Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: MTNR1A
• [Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement](/hypothesis/h-fd1562a3) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: COX4I1

Related Analyses:

• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;
• [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;